|
|
|
|
| LEADER |
00000nam a22000005i 4500 |
| 001 |
b3228704 |
| 003 |
MWH |
| 005 |
20191026213420.0 |
| 007 |
cr nn 008mamaa |
| 008 |
121230s2004 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781592597949
|
| 024 |
7 |
|
|a 10.1007/978-1-59259-794-9
|2 doi
|
| 035 |
|
|
|a (DE-He213)978-1-59259-794-9
|
| 050 |
|
4 |
|a E-Book
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 072 |
|
7 |
|a MJCL
|2 thema
|
| 245 |
1 |
0 |
|a Proteasome Inhibitors in Cancer Therapy
|h [electronic resource] /
|c edited by Julian Adams.
|
| 250 |
|
|
|a 1st ed. 2004.
|
| 264 |
|
1 |
|a Totowa, NJ :
|b Humana Press :
|b Imprint: Humana,
|c 2004.
|
| 300 |
|
|
|a XV, 313 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Cancer Drug Discovery and Development,
|x 2196-9906
|
| 490 |
1 |
|
|a Springer eBook Collection
|
| 505 |
0 |
|
|a I Cancer Drug Development -- 1 Cancer Drug Development: Challenges in a Competitive Market -- II Chemistry and Cell Biology of the Proteasome -- 2 Introduction to the Proteasome and Its Inhibitors: Biochemistry and Cell Biology -- 3 Structures of the Yeast Proteasome Core Particle in Complex with Inhibitors -- 4 Natural Product and Synthetic Proteasome Inhibitors -- 5 Other Proteasome Inhibitors -- 6 The Proteasome in Cell-Cycle Regulation -- 7 Proteasome Inhibition and Apoptosis -- 8 The Proteasome and the COMPARE Algorithm -- III Rationale for Proteasome Inhibitors in Cancer -- 9 The Proteasome in Cancer Biology and Therapy -- 10 Radiosensitization and Proteasome Inhibition -- 11 Proteasome-Dependent Regulation of NF-?B Activation: Molecular Targeting of Chemotherapy Resistance -- 12 Bortezomib with Taxanes -- 13 Proteasome Inhibitor Therapy in a Brain Tumor Model -- 14 Anthracyclines and Bortezomib -- 15 TNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy? -- 16 Rationale for Combining the Proteasome Inhibitor Bortezomib with Cisplatin -- 17 The Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen Presentation -- 18 Function(s) of the Ubiquitin—Proteasome System in Retrovirus Budding -- IV Clinical Trials -- 19 Preclinical Development of Bortezomib (VELCADE™): Rationale for Clinical Studies -- 20 Phase I Trials: Bortezomib Alone and in Combination With Standard Chemotherapies -- 21 Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy -- 22 Phase II Trials of Bortezomib for the Treatment of Multiple Myeloma.
|
| 520 |
|
|
|a Immediately upon the discovery some ten years ago that inhibition of the proteasome in cultured cells, mostly of tumor origin, caused the programmed cell death machinery to ramp up, it became imperative to investigate proteasome inhibition as a possible treatment for human cancers. In Proteasome Inhibitors in Cancer Therapy, Julian Adams, the leader in developing the field, brings together a panel of highly experienced academic and pharmaceutical investigators to take stock of the remarkable work that has been accomplished to date, and examine emerging therapeutic possibilities for proteasome inhibitors in cancer. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of the very empirical and practical development of rationales to test proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of proteasome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (Velcade™) through multicentered clinical trials in patients with relapsed and refractory myeloma to FDA approval, and describe how modern pharmacogenomic tools can be used to predict which patients will respond to such proteasome inhibitor therapy. Additional chapters on the proteasome's basic biochemistry review its mechanism in the cell cycle and apoptosis and suggest opportunities for using proteasome inhibitors to find additional medicinal targets. Authoritative and illuminating, Proteasome Inhibitors in Cancer Therapy makes clear that proteasome inhibition should prove a fertile area for the many future discoveries that will provide relief of suffering and extend the quality of life of patients afflicted with cancer and other debilitating diseases.
|
| 590 |
|
|
|a Loaded electronically.
|
| 590 |
|
|
|a Electronic access restricted to members of the Holy Cross Community.
|
| 650 |
|
0 |
|a Oncology .
|
| 650 |
|
0 |
|a Cancer research.
|
| 690 |
|
|
|a Electronic resources (E-books)
|
| 700 |
1 |
|
|a Adams, Julian.
|e editor.
|4 edt
|4 http://id.loc.gov/vocabulary/relators/edt
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 830 |
|
0 |
|a Cancer Drug Discovery and Development,
|x 2196-9906
|
| 830 |
|
0 |
|a Springer eBook Collection.
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/978-1-59259-794-9
|3 Click to view e-book
|
| 907 |
|
|
|a .b32287045
|b 04-18-22
|c 02-26-20
|
| 998 |
|
|
|a he
|b 02-26-20
|c m
|d @
|e -
|f eng
|g xxu
|h 0
|i 1
|
| 912 |
|
|
|a ZDB-2-SME
|
| 912 |
|
|
|a ZDB-2-BAE
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
| 902 |
|
|
|a springer purchased ebooks
|
| 903 |
|
|
|a SEB-COLL
|
| 945 |
|
|
|f - -
|g 1
|h 0
|j - -
|k - -
|l he
|o -
|p $0.00
|q -
|r -
|s b
|t 38
|u 0
|v 0
|w 0
|x 0
|y .i2141869x
|z 02-26-20
|
| 999 |
f |
f |
|i 967d435b-db2f-5c75-9d24-a782450c8aed
|s 1e4fed12-6215-5d15-8725-ed679c047a4d
|
| 952 |
f |
f |
|p Online
|a College of the Holy Cross
|b Main Campus
|c E-Resources
|d Online
|e E-Book
|h Library of Congress classification
|i Elec File
|n 1
|